{"id":1006044,"date":"2026-09-25T17:18:34","date_gmt":"2026-09-25T21:18:34","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-eight-decipher-focused-studies-to-be-presented-at-astro-2026\/"},"modified":"2026-09-25T17:18:34","modified_gmt":"2026-09-25T21:18:34","slug":"veracyte-announces-eight-decipher-focused-studies-to-be-presented-at-astro-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-eight-decipher-focused-studies-to-be-presented-at-astro-2026\/","title":{"rendered":"Veracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026"},"content":{"rendered":"<h2>\nSix oral presentations and two posters will highlight Decipher\u2019s prognostic and predictive value in identifying patients\u2019 risk of progression and likelihood of benefiting from treatment intensification<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p>SOUTH SAN FRANCISCO, Calif., Sept.  25, 2026  (GLOBE NEWSWIRE) &#8212; Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that eight studies leveraging its Decipher Prostate Genomic Classifier test and whole-transcriptome data will be presented at the 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting. The conference will take place September 26\u201330 in Boston.<\/p>\n<p>The presentations include analyses from Phase II and III clinical trials, Genomic Research for Intelligent Discovery (GRID) research, and national real-world studies. Together, they examine Decipher\u2019s prognostic value in assessing disease risk and predictive value in identifying which patients may benefit from treatment intensification, including adding androgen-deprivation therapy (ADT) to radiation.<\/p>\n<p>\u201cThe breadth of research being presented at ASTRO underscores the growing role of genomic information in helping clinicians navigate complex prostate cancer treatment decisions,\u201d said Elai Davicioni, Ph.D., Veracyte\u2019s medical director for Urology. \u201cThese presentations demonstrate how elucidating the molecular components of tumor biology may help personalize treatment decisions for patients across different stages of disease.\u201d<\/p>\n<p>The following Decipher-focused studies will be presented at ASTRO 2026:<\/p>\n<p>\n        <strong>Oral Presentations<\/strong>\n      <\/p>\n<ul>\n<li>\n          <strong>Title:\u00a0<\/strong><br \/>\n          <a href=\"https:\/\/amportal.astro.org\/sessions\/ct-01-22948\/evaluation-of-pam50-molecular-subtypes-in-post-prostatectomy-salvage-radiotherapy-an-nrg-onco-113738?utm_source=chatgpt.com\" rel=\"nofollow\" target=\"_blank\">Evaluation of PAM50 Molecular Subtypes in Post-Prostatectomy Salvage Radiotherapy: An NRG Oncology-RTOG 0534 Analysis<\/a><br \/>\n          <br \/>\n          <strong>Presenter<\/strong>: Shuang Zhao, M.D., M.S.E.<br \/><strong>Abstract:<\/strong> 6<br \/><strong>Date\/Time<\/strong>: Sunday, September 27, 1:30\u20131:40 p.m. ET<br \/><strong>Location:<\/strong> Grand Ballroom<\/p>\n<\/li>\n<li>\n          <strong>Title:\u00a0<\/strong><br \/>\n          <a href=\"https:\/\/amportal.astro.org\/sessions\/ss-29-22887\/the-role-of-docetaxel-in-addition-to-salvage-radiation-and-androgen-deprivation-in-men-with-h-112063?utm_source=chatgpt.com\" rel=\"nofollow\" target=\"_blank\">The Role of Docetaxel In Addition to Salvage Radiation and Androgen Deprivation In Men with High Risk Prostate Cancer Post-Prostatectomy: Results of NRG GU002<\/a><br \/>\n          <br \/>\n          <strong>Presenter:<\/strong> Mark Hurwitz, M.D., FASTRO<br \/><strong>Abstract: <\/strong>250<br \/><strong>Date\/Time:<\/strong> Tuesday, September 29, 12:40\u201312:50 p.m. ET<br \/><strong>Location:<\/strong> Room 210<\/p>\n<\/li>\n<li>\n          <strong>Title:\u00a0<\/strong><br \/>\n          <a href=\"https:\/\/amportal.astro.org\/sessions\/ss-36-22888\/genomic-stratification-of-benefit-from-short-term-androgen-deprivation-with-dose-escalated-ra-112070?utm_source=chatgpt.com\" rel=\"nofollow\" target=\"_blank\">Genomic Stratification of Benefit From Short-Term Androgen Deprivation With Dose-Escalated Radiotherapy in Intermediate-Risk Prostate Cancer: An Ancillary Study of RTOG\/NRG 0815<\/a><br \/>\n          <br \/>\n          <strong>Presenter:<\/strong> Angela Jia, M.D., Ph.D.<br \/><strong>Abstract:<\/strong> 312<br \/><strong>Date\/Time<\/strong>: Tuesday, September 29, 3:55\u2013 4:05 p.m. ET<br \/><strong>Location:<\/strong> Room 210<\/p>\n<\/li>\n<li>\n          <strong>Title:\u00a0<\/strong><br \/>\n          <a href=\"https:\/\/amportal.astro.org\/sessions\/ss-36-22888\/multi-institutional-transcriptomic-characterization-of-radiorecurrent-prostate-cancer-and-pro-112072?utm_source=chatgpt.com\" rel=\"nofollow\" target=\"_blank\">Multi-institutional Transcriptomic Characterization of Radiorecurrent Prostate Cancer and Prognostic Biomarkers After Salvage Re-irradiation in the F-SHARP Clinical Trial<\/a><br \/>\n          <br \/>\n          <strong>Presenter:<\/strong> Abhishek Solanki, M.D., M.S.<br \/><strong>Abstract:<\/strong> 314<br \/><strong>Date\/Time:<\/strong> Tuesday, September 29, 4:15\u20134:25 p.m. ET<br \/><strong>Location<\/strong>: Room 210<\/p>\n<\/li>\n<li>\n          <strong>Title:\u00a0<\/strong><br \/>\n          <a href=\"https:\/\/amportal.astro.org\/sessions\/ss-36-22888\/long-term-transcriptomic-analysis-of-nrg-rtog-9601-a-phase-3-study-of-salvage-radiotherapy-fo-112073?utm_source=chatgpt.com\" rel=\"nofollow\" target=\"_blank\">Long-Term Transcriptomic Analysis of NRG\/RTOG 9601: A Phase 3 Study of Salvage Radiotherapy for Prostate Cancer with or without Anti-Androgen Therapy<\/a><br \/>\n          <br \/>\n          <strong>Presenter:<\/strong> Krishnan Patel, M.D.<br \/><strong>Abstract:<\/strong> 315<br \/><strong>Date\/Time:<\/strong> Tuesday, September 29, 4:25\u20134:35 p.m. ET<br \/><strong>Location:<\/strong> Room 210<\/li>\n<\/ul>\n<p>\n        <strong>Quick-Pitch Presentation<\/strong>\n      <\/p>\n<ul>\n<li>\n          <strong>Title:\u00a0<\/strong><br \/>\n          <a href=\"https:\/\/amportal.astro.org\/sessions\/qp-28-22892\/real-world-evidence-across-prostate-rt-modalities-utilization-shifts-toxicity-and-bcr-in-geno-112106?utm_source=chatgpt.com\" rel=\"nofollow\" target=\"_blank\">Real-World Evidence across Prostate RT Modalities: Utilization Shifts, Toxicity and BCR in Genomic Classifier Scored Patients<\/a><br \/>\n          <br \/>\n          <strong>Presenter:<\/strong> Thomas Kole, M.D., Ph.D.<br \/><strong>Abstract:<\/strong> 1166<br \/><strong>Date\/Time:<\/strong> Tuesday, September 29, 5:35\u20135:40 p.m. ET<br \/><strong>Location:<\/strong> Room 205<\/li>\n<\/ul>\n<p>\n        <strong>Poster Presentations<\/strong>\n      <\/p>\n<ul>\n<li>\n          <strong>Title:\u00a0<\/strong><br \/>\n          <a href=\"https:\/\/amportal.astro.org\/sessions\/pqa-06-22881\/preoperative-biopsy-genomic-classifier-and-secondary-radiotherapy-after-radical-prostatectomy-112174?utm_source=chatgpt.com\" rel=\"nofollow\" target=\"_blank\">Preoperative Biopsy Decipher Prostate Genomic Classifier Predicts Earlier Secondary Radiotherapy After Radical Prostatectomy in National Real-World Data<\/a><br \/>\n          <br \/>\n          <strong>Presenter:<\/strong> Thomas Kole, M.D., Ph.D.<br \/><strong>Abstract:<\/strong> 3297<br \/><strong>Date\/Time:<\/strong> Sunday, September 27, 2:15\u20133:30 p.m. ET<br \/><strong>Location:<\/strong> Poster Hall, Exhibit Hall A<\/p>\n<\/li>\n<li>\n          <strong>Title:\u00a0<\/strong><br \/>\n          <a href=\"https:\/\/amportal.astro.org\/sessions\/pqa-06-22881\/association-of-22-gene-genomic-classifier-with-adt-use-with-secondary-radiotherapy-a-national-114310?utm_source=chatgpt.com\" rel=\"nofollow\" target=\"_blank\">Association of 22-Gene Genomic Classifier with ADT Use with Secondary Radiotherapy: A National Real-World Analysis<\/a><br \/>\n          <br \/>\n          <strong>Presenter:<\/strong> Andrew Barsky, M.D.<br \/><strong>Abstract:<\/strong> 3226<br \/><strong>Date\/Time:<\/strong> Tuesday, September 29, 2:15\u20133:30 p.m. ET<br \/><strong>Location:<\/strong> Poster Hall, Exhibit Hall A<\/li>\n<\/ul>\n<p>Additional information is available through the ASTRO 2026 Annual Meeting program.<\/p>\n<p>\n        <strong>About Veracyte<\/strong>\n      <\/p>\n<p>Veracyte\u202f(Nasdaq: VCYT) is a global diagnostics company with a vision to transform cancer care for patients around the world.\u202fThe company\u2019s molecular tests assess the unique biology of each patient\u2019s tumor to help clinicians answer essential questions about cancer care.\u202f<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=g8UAlJlDZyMbXZdAnlL-qcDqasQZShsXtBe8j0k7uvnmsB-Kf2z9JqeryL5gVgrvK-48O6rDVUuF5CCAGK7RPg-UZdiJnFSgIrZ9dJqdpcVrD1_4gCkYnKZ2u5koU-HK2xrhJGqTjA-WJzK7HC7R4HrntJpwfj1Bvd_wsO2eHjg=\" rel=\"nofollow\" target=\"_blank\">Veracyte\u2019s Diagnostics Platform<\/a>\u202fcombines broad genomic and clinical data, advanced bioinformatics and AI, and a\u202fpowerful\u202fevidence-generation engine to\u202fsupport continued\u202f<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=W4oYpQ8MJtRXGMZN594PEa8Ni1kfHfuL_yldsj_SPo_P8uP2tqRyLuPNoBuGNDTJjEqjP7lGxJE0vsi6ZzqK-7L333w8LcVwaHDb_Wrf_1bK2MYBnUtQmaQwgxKAZbFKGyuKAlZcA1zT4hG43xcoM50FiBD7Q1SESIKCgHdzTjg=\" rel=\"nofollow\" target=\"_blank\">innovation and pipeline development<\/a>. The company\u2019s portfolio includes the\u202f<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Yk5Xw21xeT4mJltv2dpqCvcpsvePtfWGZsKZZdywRvx105W9CuNwvCZP6YvcuIhxnnx18qj_9m1IYQfcO5oZkusBfK4PsBI4c5fH91Z9eL9SDts9uaikXWL2EV9QXkBo0FhbanfqpsCtB-rthkxyTi5zd8HUNnMHnuxV9mIUknI=\" rel=\"nofollow\" target=\"_blank\">Afirma\u00ae Genomic Sequencing Classifier test<\/a>,\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FKECfKsOrsKq_UrewRqB13Z3EmNlEQfWxzH3h_-Qeukl5TpE6jZIViPQUq7OMpnNqUjqEem9uEfiNTCY5lf1taNi8yDjKWDeiq0bh2UUkCSB9J-Sh7gQcGmANtHVdgKf5VmbzlgV6Rsd32pH1aRCKxVPufCpEnrdo7UiBlWNXOY=\" rel=\"nofollow\" target=\"_blank\">Decipher\u00ae Bladder Genomic Classifier test<\/a>,\u202f<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FKECfKsOrsKq_UrewRqB1y_iBOmRqZxUI97hzB8dgnQwpWxwupgPBItbcP48JJimzv0rrzdpL2eCYn66RSnM6v52Cfz4GqDLOY0I_Kt6B9VwQ9QYC1AmbfMTisg3FzR29VustbanrW9v31XED-AIA8r_fnQ4xA3WSy1af4Gb2D4=\" rel=\"nofollow\" target=\"_blank\">Decipher\u00ae Prostate Genomic Classifier test<\/a>,\u202f<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GIKh6OA87XsoSak4QMJ7QxgJjNtiLrYaw4zZWzEZJcm9T23yf6-5et2Ii8YLTrrw3bUMkaZdZMVMUnejbSCOZRa-Gt79y12wsWg2zPVyoqTC_7lFXQbOOf5a62PnQ-wdsdmyvX07mRc39upkTPzeZw==\" rel=\"nofollow\" target=\"_blank\">Prosigna\u00ae Breast Risk of Recurrence test<\/a>, and the\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=BT9imtZ3nBjNYSVZyf9Z0oMA-syonVDywNKGLl1aM_-tp-EAI1cmm8rbbYPPvJ8_yAggnvom0-i4NXZJREnXQvyYMYvd8iunp7rgAeQQbBFrvO6hHl4HN0TX1IvLYq-l_3umpQJ2fDkT8ldQ7_15Ow==\" rel=\"nofollow\" target=\"_blank\">TrueMRD\u2122 Monitoring Test for MIBC<\/a>.\u202fFor more information, visit\u202fVeracyte\u2019s\u202f<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=mO9Mmt4xlFJJa3_nT84S3FKuyPorMIDzbkvRqGDKq72SwRZQHTVTML7tKCR6KtioVH6uUfeg4f-AGyy5YsAQjg==\" rel=\"nofollow\" target=\"_blank\">website<\/a>\u202for follow the company on\u202f<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=K7GQlEbSvAVK8Pzl3wNUE2zrolU_QaSCz4Tv_Gsk-klQbHXjrzp25Z42UP-DNb4jAIQD5Bbf5YlHYHUr5uq0E7Q4pysv6zjZo0keL-exPy0=\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>\u202for\u202f<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=uWDNyKyNQRAGYT-xMXjlwNMkxJ13IdePTDSG1rgPpF0x1JO9c0Pt8jUNqNCswcO9KVg7_mJJhRw38bM-bCTgzA==\" rel=\"nofollow\" target=\"_blank\">X (Twitter)<\/a>.\u202f\u00a0<\/p>\n<p>\n        <strong>Cautionary Note Regarding Forward-Looking Statements<\/strong>\n      <\/p>\n<p>This press release contains forward-looking statements, including but not limited to statements regarding the potential role of genomic information in helping identify which patients may benefit from treatment intensification and helping clinicians navigate prostate cancer treatment decisions and personalize treatment decisions for patients across different stages of disease. Forward-looking statements can be identified by words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201cexpect,\u201d \u201cmay,\u201d \u201cpotential,\u201d \u201cwill,\u201d and similar expressions. Actual results may differ materially from those expressed or implied by these statements due to risks and uncertainties described under the caption \u201cRisk Factors\u201d in Veracyte\u2019s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this release, and Veracyte disclaims any obligation to update them except as required by law.<\/p>\n<p>Veracyte, the Veracyte logo and Decipher are registered trademarks of Veracyte, Inc. and its subsidiaries in the United States and selected countries.<\/p>\n<p>\n        <strong>Investors<\/strong>:\u00a0<br \/>Kelly Gura\u00a0\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ovgHnSp9fj-0dGK-J72_sLulmZHMBd9LRvd_R_kkmwybSjlcM_qzp-gPzdvtbB93Be7UX4tiukYrpvY8kqM688MetGGErQVC5jfMDc0PK24=\" rel=\"nofollow\" target=\"_blank\">investors@veracyte.com<\/a><\/p>\n<p>\n        <strong>Media<\/strong>:\u00a0<br \/>Molly\u00a0Cornbleet\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=A-lvn1toUY8md6VzHszZVxFyDWAV31ag5MEuuOrdzxQYUIYFSPtg4Xnn--uDdyNCnX5H0un75trOg8pJQ5Z-G9iQQyUOxjUGSg1X2-yDju8=\" rel=\"nofollow\" target=\"_blank\">media@veracyte.com<\/a>\u00a0<br \/>+1 650-351-8780<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNDM3MyM3ODYzNTE4IzIwMDY2ODg=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NjY1MzVmYTItNzQ1Mi00OTRkLTg2OTUtNzhjNmQ3NGZhN2M1LTEwMTgyNjEtMjAyNi0wOS0yNS1lbg==\/tiny\/Veracyte-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Six oral presentations and two posters will highlight Decipher\u2019s prognostic and predictive value in identifying patients\u2019 risk of progression and likelihood of benefiting from treatment intensification SOUTH SAN FRANCISCO, Calif., Sept. 25, 2026 (GLOBE NEWSWIRE) &#8212; Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that eight studies leveraging its Decipher Prostate Genomic Classifier test and whole-transcriptome data will be presented at the 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting. The conference will take place September 26\u201330 in Boston. The presentations include analyses from Phase II and III clinical trials, Genomic Research for Intelligent Discovery (GRID) research, and national real-world studies. Together, they examine Decipher\u2019s prognostic value in assessing disease risk and predictive value in identifying &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-eight-decipher-focused-studies-to-be-presented-at-astro-2026\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Veracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1006044","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Veracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-eight-decipher-focused-studies-to-be-presented-at-astro-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Veracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Six oral presentations and two posters will highlight Decipher\u2019s prognostic and predictive value in identifying patients\u2019 risk of progression and likelihood of benefiting from treatment intensification SOUTH SAN FRANCISCO, Calif., Sept. 25, 2026 (GLOBE NEWSWIRE) &#8212; Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that eight studies leveraging its Decipher Prostate Genomic Classifier test and whole-transcriptome data will be presented at the 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting. The conference will take place September 26\u201330 in Boston. The presentations include analyses from Phase II and III clinical trials, Genomic Research for Intelligent Discovery (GRID) research, and national real-world studies. Together, they examine Decipher\u2019s prognostic value in assessing disease risk and predictive value in identifying &hellip; Continue reading &quot;Veracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-eight-decipher-focused-studies-to-be-presented-at-astro-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-25T21:18:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNDM3MyM3ODYzNTE4IzIwMDY2ODg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-announces-eight-decipher-focused-studies-to-be-presented-at-astro-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-announces-eight-decipher-focused-studies-to-be-presented-at-astro-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Veracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026\",\"datePublished\":\"2026-09-25T21:18:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-announces-eight-decipher-focused-studies-to-be-presented-at-astro-2026\\\/\"},\"wordCount\":819,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-announces-eight-decipher-focused-studies-to-be-presented-at-astro-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzNDM3MyM3ODYzNTE4IzIwMDY2ODg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-announces-eight-decipher-focused-studies-to-be-presented-at-astro-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-announces-eight-decipher-focused-studies-to-be-presented-at-astro-2026\\\/\",\"name\":\"Veracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-announces-eight-decipher-focused-studies-to-be-presented-at-astro-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-announces-eight-decipher-focused-studies-to-be-presented-at-astro-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzNDM3MyM3ODYzNTE4IzIwMDY2ODg=\",\"datePublished\":\"2026-09-25T21:18:34+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-announces-eight-decipher-focused-studies-to-be-presented-at-astro-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-announces-eight-decipher-focused-studies-to-be-presented-at-astro-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-announces-eight-decipher-focused-studies-to-be-presented-at-astro-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzNDM3MyM3ODYzNTE4IzIwMDY2ODg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzNDM3MyM3ODYzNTE4IzIwMDY2ODg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-announces-eight-decipher-focused-studies-to-be-presented-at-astro-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Veracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Veracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-eight-decipher-focused-studies-to-be-presented-at-astro-2026\/","og_locale":"en_US","og_type":"article","og_title":"Veracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026 - Market Newsdesk","og_description":"Six oral presentations and two posters will highlight Decipher\u2019s prognostic and predictive value in identifying patients\u2019 risk of progression and likelihood of benefiting from treatment intensification SOUTH SAN FRANCISCO, Calif., Sept. 25, 2026 (GLOBE NEWSWIRE) &#8212; Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that eight studies leveraging its Decipher Prostate Genomic Classifier test and whole-transcriptome data will be presented at the 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting. The conference will take place September 26\u201330 in Boston. The presentations include analyses from Phase II and III clinical trials, Genomic Research for Intelligent Discovery (GRID) research, and national real-world studies. Together, they examine Decipher\u2019s prognostic value in assessing disease risk and predictive value in identifying &hellip; Continue reading \"Veracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-eight-decipher-focused-studies-to-be-presented-at-astro-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-09-25T21:18:34+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNDM3MyM3ODYzNTE4IzIwMDY2ODg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-eight-decipher-focused-studies-to-be-presented-at-astro-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-eight-decipher-focused-studies-to-be-presented-at-astro-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Veracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026","datePublished":"2026-09-25T21:18:34+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-eight-decipher-focused-studies-to-be-presented-at-astro-2026\/"},"wordCount":819,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-eight-decipher-focused-studies-to-be-presented-at-astro-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNDM3MyM3ODYzNTE4IzIwMDY2ODg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-eight-decipher-focused-studies-to-be-presented-at-astro-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-eight-decipher-focused-studies-to-be-presented-at-astro-2026\/","name":"Veracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-eight-decipher-focused-studies-to-be-presented-at-astro-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-eight-decipher-focused-studies-to-be-presented-at-astro-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNDM3MyM3ODYzNTE4IzIwMDY2ODg=","datePublished":"2026-09-25T21:18:34+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-eight-decipher-focused-studies-to-be-presented-at-astro-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-eight-decipher-focused-studies-to-be-presented-at-astro-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-eight-decipher-focused-studies-to-be-presented-at-astro-2026\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNDM3MyM3ODYzNTE4IzIwMDY2ODg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNDM3MyM3ODYzNTE4IzIwMDY2ODg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-eight-decipher-focused-studies-to-be-presented-at-astro-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Veracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1006044","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1006044"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1006044\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1006044"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1006044"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1006044"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}